Subscribe for free and join 4,200 other investors to make sure you dont miss our next briefing: A quick update on our buy recommendations before we jump in The Trade Desk: Just joined the S&P 500 and is up 18% vs 4.5% for the S&P 500 ASML Holding: ASML had an earnings beat, but is down 6% due to weak guidance AMD: Got approval to sell chips to China and is up 11% vs -0.3% for the S&P 500 As always, here is our complete tracker in one place
Our review of the clinical trial pipeline reveals 39 new GLP-1 drugs in development from 34 companies, with only seven among the top 20 pharmaceutical companies
Diet and Lifestyle Integration A Balanced Approach: We advocate for a balanced diet and lifestyle changes that complement the effects of GLP-1 medications, offering a sustainable path to weight loss
We use lab history medical history and information collected by our providers to submit to your insurance
Some pharmacies and facilities previously made compounded tirzepatide, but this was only allowed while there was a national shortage
The diabetes-specific TRANSCEND-T2D-1 population tolerated it better (5.1%)